For this annual special report, which is in its 31st year of publication, Med Ad News editors rank and profile the world’s top 50 companies that generate revenue from healthcare products.
For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
While the world’s leading prescription drug Humira still accounts for the majority of AbbVie’s revenue, plenty else is bubbling up at the almost-five-year-old company.
Amgen is featuring an unprecedented collection of new product offerings, including the first-ever biosimilar cancer treatment to receive U.S. marketing clearance.
Although patent expirations continue to depress revenue, AstraZeneca executives believe in the pipeline.
For Bayer, the acquisition of Monsanto is intended to build its Crop Science division; meanwhile two significant approvals and two new hires enhance progress in oncology.
After years of hope and hype, Bristol-Myers Squibb’s centerpiece immuno-oncologic Opdivo is delivering the dollars.
With sales of Harvoni and Sovaldi falling off, Gilead welcomed two new blockbusters to the company’s portfolio in 2016.
Management set out a series of new priorities to 2020 to improve innovation, performance and trust in GlaxoSmithKline.
With proven worldwide commercial capabilities and a robust product pipeline, Johnson & Johnson is firmly positioned to continue generating strong, long-term, sustainable growth.
